Toward Next Generation Lateral Flow Assays: Integration of Nanomaterials
Universitat de València · Institut Català de Nanociència i Nanotecnologia · +4 more institutions
Abstract
Lateral flow assays (LFAs) are currently the most used point-of-care sensors for both diagnostic (e.g., pregnancy test, COVID-19 monitoring) and environmental (e.g., pesticides and bacterial monitoring) applications. Although the core of LFA technology was developed several decades ago, in recent years the integration of novel nanomaterials as signal transducers or receptor immobilization platforms has brought improved analytical capabilities. In this Review, we present how nanomaterial-based LFAs can address the inherent challenges of point-of-care (PoC) diagnostics such as sensitivity enhancement, lowering of detection limits, multiplexing, and quantification of analytes in complex samples. Specifically, we…
Citation impact
- FWCI
- 22.55
- Percentile
- 100%
- References
- 171
Authors
5- ASAmadeo Sena‐Torralba
Universitat de València, Institut Català de Nanociència i Nanotecnologia, Universitat Politècnica de València
- RÁRuslán Álvarez-Diduk
Institut Català de Nanociència i Nanotecnologia
- CPClaudio Parolo
Barcelona Institute for Global Health, Universitat de Barcelona
- APAndrew Piper
Institut Català de Nanociència i Nanotecnologia
- AMArben MerkoçiCorresponding
Institució Catalana de Recerca i Estudis Avançats, Institut Català de Nanociència i Nanotecnologia
Topics & keywords
- Commercialization
- Nanotechnology
- Nanomaterials
- Point-of-care testing
- Point of care
- Biochemical engineering
- Chemistry
- Computer science
Funding
- CDCentres de Recerca de CatalunyaAwards: CEX2018-000806-S, 501100011033, MCIN/AEI/10.13039/501100011033
- ICInstitut Català de Nanociència i Nanotecnologia
- GFGraphene FlagshipAwards: 881603, Core 3
- ECEuropean CommissionAwards: 10.13039/501100011033, MCIN/ AEI/10.13039/501100011033, 13039/501100011033, 501100011033, 881603, COVID-19, 825694, AEI/10.13039/501100011033, MCIN/AEI/ 10.13039/501100011033, 2019-2023, 795635, MCIN/AEI/10.13039/501100011033, COVID19
- GDGeneralitat de CatalunyaAwards: 10.13039/501100011033, SEV-2017-0706, 501100011033, MCIN/AEI/10.13039/501100011033, CEX2018-000806-S, MCIN/ AEI/10.13039/501100011033, MCIN/AEI/ 10.13039/501100011033
- MDMinisterio de Ciencia e InnovaciónAwards: AEI/ 10.13039/501100011033, MCIN/AEI/10, MCIN/AEI/ 10.13039/501100011033, 10.13039, MCIN/ AEI/10.13039/501100011033, / AEI/10, / AEI/10.13039/501100011033, PID2021-124795NB-I00, AEI/10.13039/501100011033, MCIN/ AEI/10, 10.13039/501100011033/, Centro de Excelencia Severo Ochoa 2019-2023, 501100011033, AEI/10, CEX2018-000806-S, SEV-2017-0706, MCIN/AEI/10., funded by MCIN/AEI/10.13039/501100011033, MCIN/AEI/10.13039/501100011033, 10.13039/501100011033, 13039/501100011033, /AEI/10.13039/501100011033, MCIN/AEI/10.13039
- MDMinisterio de Asuntos Económicos y Transformación Digital, Gobierno de EspañaAward: FJC2020-043927-I
- H2Horizon 2020 Framework ProgrammeAwards: 795635, 825694, 881603
- CSConsejo Superior de Investigaciones CientíficasAwards: MCIN/AEI/10.13039/501100011033, AEI/10.13039/501100011033, MCIN/ AEI/10.13039/501100011033, SEV-2017-0706, COVID19-122
- IDInstituto de Salud Carlos IIIAwards: MCIN/AEI/10.13039/501100011033, /10.13039/501100011033, CEX2018-000806-S, AC21_2/00044, AEI/10.13039/501100011033
- EREuropean Regional Development FundAwards: SEV-2017-0706, PLEC2021-007972
- AEAgencia Estatal de InvestigaciónAwards: AEI/10.13039/501100011033, 501100011033, by MCIN/AEI/10.13039/501100011033, 10.13039/501100011033, MCIN/ AEI/10.13039/501100011033, MCIN/AEI/10.13039/501100011033, AEI/ 10.13039/501100011033, 13039, 10.13039, 13039/501100011033/, SEV-2017-0706, PID2021-124795NB-I00, AEI/10, CEX2018-000806-S, 13039/501100011033, AEI/10., MCIN/AEI/ 10.13039/501100011033
- HMH2020 Marie Skłodowska-Curie ActionsAwards: MCIN/AEI/10.13039/501100011033, 795635, 881603, Horizon 2020